CN101031555A - 具有vap－1抑制活性的噻唑衍生物 - Google Patents

具有vap－1抑制活性的噻唑衍生物 Download PDF

Info

Publication number
CN101031555A
CN101031555A CNA200580031703XA CN200580031703A CN101031555A CN 101031555 A CN101031555 A CN 101031555A CN A200580031703X A CNA200580031703X A CN A200580031703XA CN 200580031703 A CN200580031703 A CN 200580031703A CN 101031555 A CN101031555 A CN 101031555A
Authority
CN
China
Prior art keywords
amino
methyl
ethyl
phenyl
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200580031703XA
Other languages
English (en)
Chinese (zh)
Inventor
井上隆幸
东条隆
森田真正
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R Tech Ueno Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004904196A external-priority patent/AU2004904196A0/en
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of CN101031555A publication Critical patent/CN101031555A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA200580031703XA 2004-07-27 2005-07-27 具有vap－1抑制活性的噻唑衍生物 Pending CN101031555A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004904196 2004-07-27
AU2004904196A AU2004904196A0 (en) 2004-07-27 Thiazole Derivatives Having VAP-1 Inhibitory Activity

Publications (1)

Publication Number Publication Date
CN101031555A true CN101031555A (zh) 2007-09-05

Family

ID=35734947

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200580031703XA Pending CN101031555A (zh) 2004-07-27 2005-07-27 具有vap－1抑制活性的噻唑衍生物

Country Status (10)

Country Link
US (1) US20070254931A1 (enExample)
EP (1) EP1786792B1 (enExample)
JP (1) JP4978464B2 (enExample)
KR (1) KR20070050932A (enExample)
CN (1) CN101031555A (enExample)
AT (1) ATE427941T1 (enExample)
CA (1) CA2575411A1 (enExample)
DE (1) DE602005013793D1 (enExample)
ES (1) ES2324922T3 (enExample)
WO (1) WO2006011631A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103459369A (zh) * 2011-03-15 2013-12-18 安斯泰来制药株式会社 胍化合物
CN107661500A (zh) * 2009-09-08 2018-02-06 生物结治疗公司 Vap‑1抑制剂用于治疗纤维变性疾病的用途
CN107922379A (zh) * 2015-08-06 2018-04-17 宇部兴产株式会社 取代胍衍生物
CN110114350A (zh) * 2016-12-28 2019-08-09 宇部兴产株式会社 取代胍化合物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641766A1 (en) * 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
CN101484433A (zh) 2006-02-15 2009-07-15 艾博特公司 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
US20100190834A1 (en) * 2007-06-25 2010-07-29 R-Tech Ueno, Ltd. Composition for ophtalmic disease associated with hypoxia or ischemia
CA2702885A1 (en) * 2007-10-19 2009-04-23 R-Tech Ueno, Ltd. Pharmaceutical composition for treatment of cataract
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
CA2712262A1 (en) * 2008-01-18 2009-07-23 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
TWI437986B (zh) 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
NZ592603A (en) * 2008-10-21 2013-02-22 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
JP6050238B2 (ja) 2011-10-19 2016-12-21 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015159112A1 (en) 2014-04-15 2015-10-22 Pécsi Tudományegyetem Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
CN104478828B (zh) * 2014-12-10 2016-07-06 漳州片仔癀药业股份有限公司 2-氨基-7-取代苯并噻唑类化合物及其制备方法与用途
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JP2018076236A (ja) 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
CA3007768A1 (en) 2015-12-07 2017-06-15 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
EA037188B1 (ru) * 2016-05-12 2021-02-17 Бёрингер Ингельхайм Интернациональ Гмбх Пиридинильные производные, фармацевтические композиции и их применение в качестве ингибиторов аос3
US10213306B2 (en) 2017-03-31 2019-02-26 Neochord, Inc. Minimally invasive heart valve repair in a beating heart

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511574A (en) * 1981-01-08 1985-04-16 Mitsui Toatsu Kagaku Kabushiki Kaisha N-(4-Phenyl-2-thiazolyl)carbamate derivatives
US4699928A (en) * 1984-07-13 1987-10-13 Merrell Dow Pharmaceuticals Inc. Fluoroallylamine derivatives
IT1181871B (it) * 1985-04-01 1987-09-30 Consiglio Nazionale Ricerche Inibitori selettivi delle benzilamminossidasi rispetto ad altre amminossidasi
US4650907A (en) * 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4943593A (en) * 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) * 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) * 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059814A (en) * 1988-11-30 1991-10-22 The California Institute Of Technology Winner-take-all circuits for neural computing systems
JPH0848664A (ja) * 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc 新規なグアニジノ安息香酸エステル誘導体
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives
PL360374A1 (en) * 2000-07-05 2004-09-06 Biotie Therapies Corporation Inhibitors of copper-containing amine oxidases
AU2002214505A1 (en) * 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
US7125901B2 (en) * 2003-01-27 2006-10-24 Astellas Pharma Inc. Thiazole derivatives
JP4758337B2 (ja) * 2003-03-31 2011-08-24 株式会社アールテック・ウエノ 血管透過性亢進疾患を治療する方法
JP4881159B2 (ja) * 2004-03-18 2012-02-22 株式会社アールテック・ウエノ チアゾール誘導体を含む水性組成物

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107661500A (zh) * 2009-09-08 2018-02-06 生物结治疗公司 Vap‑1抑制剂用于治疗纤维变性疾病的用途
CN103459369A (zh) * 2011-03-15 2013-12-18 安斯泰来制药株式会社 胍化合物
CN103459369B (zh) * 2011-03-15 2015-05-27 安斯泰来制药株式会社 胍化合物
US9051283B2 (en) 2011-03-15 2015-06-09 Astellas Pharma Inc. Guanidine compound
US9556160B2 (en) 2011-03-15 2017-01-31 Astellas Pharma Inc. Guanidine compound
CN107922379A (zh) * 2015-08-06 2018-04-17 宇部兴产株式会社 取代胍衍生物
US10759781B2 (en) 2015-08-06 2020-09-01 Ube Industries, Ltd. Substituted guanidine derivatives
CN107922379B (zh) * 2015-08-06 2020-11-06 宇部兴产株式会社 取代胍衍生物
CN110114350A (zh) * 2016-12-28 2019-08-09 宇部兴产株式会社 取代胍化合物
CN110114350B (zh) * 2016-12-28 2022-03-04 宇部兴产株式会社 取代胍化合物

Also Published As

Publication number Publication date
EP1786792B1 (en) 2009-04-08
WO2006011631A2 (en) 2006-02-02
EP1786792A2 (en) 2007-05-23
JP2008508188A (ja) 2008-03-21
US20070254931A1 (en) 2007-11-01
WO2006011631A3 (en) 2006-04-20
ES2324922T3 (es) 2009-08-19
DE602005013793D1 (de) 2009-05-20
JP4978464B2 (ja) 2012-07-18
CA2575411A1 (en) 2006-02-02
ATE427941T1 (de) 2009-04-15
KR20070050932A (ko) 2007-05-16

Similar Documents

Publication Publication Date Title
CN101031555A (zh) 具有vap－1抑制活性的噻唑衍生物
CN1149214C (zh) 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂
CN1946703A (zh) 取代的噻唑和嘧啶衍生物作为黑素细胞皮质激素受体调节剂
CN1897936A (zh) 环状胍、含有这种化合物的组合物及其使用方法
CN1913886A (zh) 杂环天冬氨酰蛋白酶抑制剂
CN1659147A (zh) 哒嗪衍生物
CN1659148A (zh) 芳基肟化合物
CN1080720C (zh) 噻唑衍生物
CN1107839A (zh) 甲酰胺类化合物
CN1118595A (zh) 氨茴酸衍生物
CN1094028A (zh) 选择性的磷酸二酯酶(ⅳ)抑制剂儿茶酚二醚类
CN1608067A (zh) 作为磷酸二酯酶vii抑制剂的吡咯并嘧啶化合物
CN1703397A (zh) 磺酰基氨基－乙酸衍生物及其作为阿立新受体拮抗剂的应用
CN1922139A (zh) 双环酰胺衍生物
CN1344160A (zh) 用作生长激素促分泌剂的杂环芳族化合物
CN1794988A (zh) 用于治疗血管渗透性过高疾病的方法
CN1305454A (zh) 作为cgmp－磷酸二酯酶抑制剂的邻氨基苯甲酸衍生物
CN1291184A (zh) 环烯衍生物、其制造方法和用途
CN1620442A (zh) 五元环化合物
CN1674892A (zh) 杂联芳基衍生物作为基质金属蛋白酶抑制剂
CN1119856A (zh) Hiv逆转录酶抑制剂
CN1655780A (zh) 用作前列腺素受体调节剂的噻唑烷甲酰胺衍生物
CN1030701C (zh) 吲哚衍生物的制备方法
CN1035817C (zh) 三唑基取代的叔胺化合物及其盐的制备方法
CN1639133A (zh) 新抗菌化合物、其制备方法和含有它们的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: R-TECH UENO, LTD.

Free format text: FORMER OWNER: ASTELLAS PHARMA INC.

Effective date: 20080307

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080307

Address after: Tokyo, Japan, Japan

Applicant after: R-Tech Ueno, Ltd.

Address before: Tokyo, Japan

Applicant before: Yamanouchi Pharma Co., Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1111145

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20070905

C20 Patent right or utility model deemed to be abandoned or is abandoned